Pipelines bulk up
As industry shakes up R&D, a surge in clinical projects spurs hope.
By Michael D. Christel
Approved medicines
From June 2008 through April 2009, 70 medicines were approved in the United States.
Awaiting approval
New drug applications and supplemental new drug applications for more than 220 drugs are awaiting approval in the United States.
Phase III clinical trials
More than 550 drugs – new chemical entities, new formulations, and new indications – are in Phase III trials in the United States.
Phase II/III clinical trials
In the United States, 28 new chemical entities, new indications, and new formulations are in Phase II/III trials.
Phase II clinical trials
More than 1,100 new chemical entities, new indications, and new formulations are being investigated in Phase II trials in the United States.
Phase I/II clinical trials
More than 160 new chemical entities, new indications, and new formulations are being investigated in Phase I/II trials in the United States.
Phase I clinical trials
More than 960 new chemical entities, new indications, and new formulations are in Phase I trials in the United States.
Editor's Page
As biotech drugs become a larger part of pipelines in many therapeutic areas, this year’s BIO convention stressed the importance of partnerships.
By Christiane Truelove
Vaccine velocity
Although the swine flu crisis has thrust vaccine development into the public consciousness, R&D expansion in the field has been years in the making
By Lyle Fitzsimmons
Experimental drug harnesses T-cell’s tumor-killing powers
Christian Itin, Ph.D., president and CEO of Micromet Inc., spoke with R&D Directions about the biotech company’s experimental and potentially revolutionary new class of constructed monoclonal antibodies, drugs designed to direct a patient’s T-cells to attack and kill tumor cells that hide beneath the bone marrow.
By Michael D. Christel
ACRO’s Doug Peddicord addresses key issues
Doug Peddicord, Ph.D., executive director with the Association of Clinical Research Organizations, spoke with R&D Directions Managing Editor Michael Christel about several key issues facing CROs and pharmaceutical companies, including comparative effectiveness research and globalization.
By Michael D. Christel
